Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Applied Materials -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (41982)	2/9/2001 6:36:09 PM
From: Sam Citron	Read Replies (1) \| Respond to of 70976

OT Ian, Now I'm completely and utterly bewildered. In a Fool Plate Special biz.yahoo.com on Monday afternoon, it was reported that "The FDA originally approved Visudyne for one cause of CNV, a condition in which abnormal blood vessels in the eye leak blood and fluid, and cause lesions and scar tissue over the central part of the eye, or macula. According to Novartis representatives, the FDA action suggests imminent approval to use Visudyne for CNV caused by two additional conditions: OHS, severe, irreversible vision loss caused by fungal infection of the retina, and the more common pathologic myopia (PM), where severe nearsightedness or myopia leads to elongation and thinning of tissue and leaky blood vessels." Then late Wednesday afternoon NVS and QLTI announce they have reason to believe that Visudyne also is effective for wet age-related macular degeneration. Is there any condition of the eye that Visudyne will not treat? I am a complete novice to the biotech/pharm sector but have a working hypothesis that the best time to get in to one of these stocks is when the FDA raises doubts or a lawsuit is lost (e.g. TKTX). Please tell me if your experience bears this out. Sam